Welcome to our dedicated page for PRECIGEN SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precigen, Inc. filings document the company’s biopharmaceutical operations, commercial product disclosures, governance matters, and capital structure. Form 8-K reports cover financial results, PAPZIMEOS business updates, investor presentations, commercial supply arrangements, and financing agreements tied to the company’s transition into commercial-stage operations.
Precigen’s proxy materials describe board elections, auditor ratification, executive compensation votes, and equity incentive plan matters. Other filings disclose its Nasdaq-listed common stock, preferred-stock conversion activity, senior secured debt arrangements, material agreements, risk factors, and corporate governance controls relevant to a public precision-medicine company.
PGEN filed a Form 144 reporting proposed sales of Common Stock. The filing lists historical issuances, private placements, RSU vesting events and a secondary public offering with per-event share counts and dates from 03/01/2013 through 07/03/2018.
Precigen, Inc. presents an annual overview as a newly commercial-stage biopharmaceutical company following full FDA approval of Papzimeos for adults with recurrent respiratory papillomatosis. In a pivotal study, 51% of 35 patients at the recommended dose achieved a complete response with durable benefit beyond 12 months.
The company estimates about 27,000 adults in the United States live with this disease and has launched Papzimeos with broad U.S. payer coverage, including approximately 215 million privately insured lives plus Medicare and Medicaid. Beyond Papzimeos, Precigen advances its AdenoVerse immunotherapy and UltraCAR-T platforms, while pausing some early UltraCAR-T trials to focus resources on lead programs.
Precigen reported a pivotal 2025 as it shifted to a commercial-stage model following FDA approval and US launch of PAPZIMEOS for recurrent respiratory papillomatosis. Total revenues were $9.7 million for the year, up from $3.9 million in 2024, driven by $3.4 million of PAPZIMEOS product revenue and higher collaboration and licensing revenue of $1.8 million.
Research and development expenses fell to $41.3 million, a $11.7 million decrease tied to pipeline prioritization and the ActoBio shutdown, while selling, general and administrative costs rose to $70.1 million as the company invested in PAPZIMEOS commercial readiness and launch. Operating loss improved modestly to $110.5 million.
Other non-operating items dominated the bottom line. A $139.5 million increase in the fair value of warrant liabilities and a $179.0 million non-cash deemed dividend on preferred stock led to a net loss attributable to common shareholders of $429.6 million, or $1.37 per share, compared with $126.2 million, or $0.47 per share, in 2024. As of December 31, 2025, cash and cash equivalents were $30.2 million and short-term investments were $67.6 million. Management expects the current cash position and PAPZIMEOS sales to fund operations through cash flow break-even by the end of 2026.
PRECIGEN, INC. Chief Financial Officer Harry Thomasian Jr. received a grant of 40,293 restricted stock units on March 18, 2026. Each RSU represents a contingent right to receive one share of Precigen common stock and the RSUs vested immediately upon grant. He then exercised the RSUs into 40,293 shares of common stock at a conversion price of $0.00 per share, bringing his directly held common stock position to 508,919 shares.
PRECIGEN, INC. Chief Commercial Officer Phil Tennant received a grant of 42,110 restricted stock units on March 18, 2026. Each RSU represents one share of common stock and vested immediately on the grant date. The RSUs were then exercised and converted into 42,110 shares of common stock at no cash exercise price, increasing his directly owned common stock holdings to 107,141 shares after these transactions. These actions reflect compensation-related equity awards and derivative exercises, not open-market buying or selling.
PRECIGEN, INC. President and CEO Helen Sabzevari received a grant of 321,100 restricted stock units on March 18, 2026, each representing one share of common stock. The RSUs vested immediately on the grant date as part of her equity compensation.
She then exercised these 321,100 RSUs at $0.00 per unit, converting them into 321,100 shares of common stock. Following the transactions, she directly holds 3,638,122 shares of Precigen common stock. These are compensation-related acquisitions, not open-market purchases.
PRECIGEN, INC. Chief Operating Officer Rutul R. Shah reported equity compensation activity in the form of restricted stock units (RSUs). On March 18, 2026, he received a grant of 44,495 RSUs, each representing one share of common stock, which vested immediately at a price of $0.00 per unit. These RSUs were then exercised and settled into 44,495 shares of Precigen common stock, increasing his direct common stock holdings to 450,454 shares following the transactions.
PRECIGEN, INC. Chief Legal Officer Donald P. Lehr reported a compensation-related equity transaction involving restricted stock units (RSUs). On March 18, 2026, he received a grant of 40,443 RSUs, each representing a contingent right to one share of common stock, at a stated price of $0.0000 per unit.
The footnotes state that these RSUs vested immediately on the grant date. On the same date, Lehr exercised the 40,443 RSUs, converting them into 40,443 shares of common stock at an exercise price of $0.0000. Following this exercise, his directly held common stock position increased to 722,092 shares, and no remaining derivative position is shown in this filing.
This sequence reflects an RSU grant and immediate vesting-and-exercise rather than an open-market purchase or sale, making it a routine equity compensation event for a senior executive.
PRECIGEN, INC. director and major shareholder Randal J. Kirk reported the vesting and exercise of 143,678 restricted stock units into an equal number of shares of common stock at an exercise price of $0.00 per share on March 13, 2026.
The shares are held indirectly through the R.J. Kirk Declaration of Trust, which now holds 81,781,816 shares of Precigen common stock. Additional Form 4 entries list indirect holdings in various trusts, LLCs and related entities that Mr. Kirk controls, with beneficial ownership disclaimed except for any pecuniary interest.
PRECIGEN, INC. director Nancy H. Agee exercised restricted stock units that converted into common shares. On March 13, 2026, 71,839 RSUs vested in full, with each RSU representing one share of Precigen common stock. Following the conversion, she directly holds 305,776 shares of common stock.
This is a compensation-related equity vesting rather than an open-market purchase or sale, and there were no shares reported as sold in connection with this transaction.